| Date | Title | Description |
| 28.10.2024 | /C O R R E C T I O N -- Seegene Inc./ | In the news release, Seegene Holds Partner Executive Roundtable with Microsoft, and Springer Nature, Accelerating its Technology-Sharing Initiative, issued 24-Oct-2024 by Seegene Inc. over PR Newswire, we are advised by the company that the... |
| 24.10.2024 | Seegene Holds Partner Executive Roundtable with Microsoft, and Springer Nature, Accelerating its Technology-Sharing Initiative | - The first tri-party executive roundtable was held in London to strengthen synergies for Seegene's vision of creating 'a world free from diseases'
- Preliminary results of product development automation and statistical analysis of syndromi... |
| 08.10.2024 | Seegene and Werfen Finalize Partnership Agreement on Technology-Sharing Initiative | Werfen, a worldwide leader in specialized diagnostics, becomes the first European company to finalize the partnership agreement to join Seegene's technology-sharing initiative
The two companies will co-establish a NewCo in Spain to serve as... |
| 13.09.2024 | Seegene's New Assays: A Lifeline in the Fight Against Mpox | In the world of infectious diseases, time is of the essence. The faster we can detect a virus, the quicker we can respond. Seegene Inc., a South Korean leader in molecular diagnostics, has stepped up to the plate. They have introduced a new... |
| 09.09.2024 | Seegene Expands mpox RUO Product Lineups with Enhanced Detection Assays for Clade 1 | Introduces Novaplex™ MPXV/OPXV plus Assay (RUO) that is designed to detect Clade I, which has higher transmission and mortality rates than Clade II
Adheres to the WHO issued target product profiles and provides accurate detection of viral s... |
| 09.09.2024 | Seegene Expands mpox RUO Product Lineups with Enhanced Detection Assays for Clade 1 | Introduces Novaplex™ MPXV/OPXV plus Assay (RUO) that is designed to detect Clade I, which has higher transmission and mortality rates than Clade II
Adheres to the WHO issued target product profiles and provides accurate detection of viral s... |
| 06.09.2024 | Seegene and Springer Nature Ignite Innovation with New Diagnostic Grants | In a world where health hangs by a thread, innovation is the lifeline. Seegene Inc., a South Korean powerhouse in molecular diagnostics, has joined forces with Springer Nature, a titan in scientific publishing. Together, they have launched ... |
| 02.09.2024 | Seegene and Springer Nature Launch 'Nature Awards MDx Impact Grants' to Innovate Syndromic PCR Diagnostic Assays | - Nature Awards MDx Impact Grants in partnership with Seegene extends commitment to external innovation.
- Global research teams invited to submit proposals to develop new tests for human infectious diseases. Application deadline: December ... |
| 02.09.2024 | Seegene and Springer Nature Launch 'Nature Awards MDx Impact Grants' to Innovate Syndromic PCR Diagnostic Assays | - Nature Awards MDx Impact Grants in partnership with Seegene extends commitment to external innovation.
- Global research teams invited to submit proposals to develop new tests for human infectious diseases. Application deadline: December ... |
| 29.08.2024 | Seegene's New PCR Tests: A Shield Against Mpox | In the world of infectious diseases, time is of the essence. The quicker we can identify a threat, the better our chances of containment. Seegene Inc., a South Korean leader in molecular diagnostics, has stepped up to the plate. With the re... |
| 26.08.2024 | Seegene Develops mpox PCR Test Assays following the WHO Global Health Emergency Declaration | - Develops NovaplexTM MPXV/OPXV Assay and NovaplexTM HSV-1&2/VZV/MPXV Assay
- Designed to detect four viruses at once using multiplex PCR technology
- Utilize dual internal controls to ensure highly reliable test results
- Pledges to su... |
| 26.08.2024 | Seegene Develops mpox PCR Test Assays following the WHO Global Health Emergency Declaration | - Develops NovaplexTM MPXV/OPXV Assay and NovaplexTM HSV-1&2/VZV/MPXV Assay
- Designed to detect four viruses at once using multiplex PCR technology
- Utilize dual internal controls to ensure highly reliable test results
- Pledges to su... |
| 05.08.2024 | Seegene Showcased its Multiplex Technology at ADLM 2024 | - Exhibited multiplex PCR testing technologies that provide comprehensive results from a single test
- Presented high-multiplex assays and automated testing systems
- Introduced the SG OneSystem™ business, the company's global technology-sh... |
| 16.07.2024 | Seegene Showcases HPV Diagnostic Kits and PCR Technology at AOGIN 2024 | Showcases Allplex™ HPV products designed to test for 14 high-risk HPV genotypes
Advocates HPV testing for early diagnosis and prevention of cervical cancer
Aims to accelerate the widespread adoption of syndromic PCR testing to create "... |
| 18.05.2024 | Seegene and Springer Nature Join Forces to Revolutionize Disease Research and Diagnosis | In a groundbreaking move, Seegene Inc. and Springer Nature have announced a strategic alliance that seeks to transform the landscape of disease research and diagnosis. This partnership, forged with the aim of fostering collaboration with re... |
| 16.05.2024 | Seegene and Springer Nature Announce Strategic Alliance | - Strategic alliance aims to foster collaboration with researchers working in various disease fields by using best-in-class PCR diagnostic technology
- Companies will facilitate C-level cooperation, strengthening the partnership for the SG ... |
| 16.05.2024 | Seegene and Springer Nature Announce Strategic Alliance | - Strategic alliance aims to foster collaboration with researchers working in various disease fields by using best-in-class PCR diagnostic technology
- Companies will facilitate C-level cooperation, strengthening the partnership for the SG ... |
| 08.04.2024 | Seegene and UK Health Security Agency convene a summit to collectively realize "a World Free from All Diseases" | Two CEOs met at Seegene headquarters to discuss and concurred with Seegene's vision
Seegene's swift responses to the COVID-19 pandemic and digital solutions through AI implementation were presented
SEOUL, South Korea, April 8, 2024 /PRNewsw... |
| 15.03.2024 | Seegene and Springer Nature Announce Awardees for the Open Innovation Program | 26 submissions selected from a total of 281 applications from 47 countries to diagnose infectious and vector-borne diseases
Awardees representing 12 countries in Europe, the Americas, Asia and Africa, will receive research grants of up to U... |
| 28.03.2023 | Seegene declares to share Syndromic PCR technologies to prevent future pandemics | Localization of Seegene Syndromic PCR technologies with global partners for versatile and proactive response to local emerging healthcare demands.
Formation of a collaborative global network to aggressively develop innovative syndromic PCR ... |
| 17.03.2022 | Seegene appoints Dr. Glen Hansen as Head of Medical Affairs of U.S. subsidiary | SEOUL, South Korea, March 17, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today announced the appointment of Glen Hansen, Ph.D., D(ABMM), FCCM, as the Head of Scientific and Medical Af... |
| 02.03.2022 | Seegene appoints Richard Creager as CEO of U.S. subsidiary to bolster U.S. business | SEOUL, South Korea, March 2, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today announced the appointment of Richard S. Creager, Ph.D., as the CEO of its United States subsidiary, Seege... |
| 19.01.2022 | Seegene to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing | SEOUL, South Korea, Jan. 19, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, announced today the upcoming launch of the Allplex™ SARS-CoV-2 Fast PCR Assay, which can deliver PCR results in... |
| 17.01.2022 | Seegene Continues to Support Israel's Effort to Manage the Omicron Variant With Timely Delivery of Five Million Tests | SEOUL, South Korea, Jan. 17, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, announced today that it has delivered over five million COVID-19 tests to Israel to help detect and mitigate th... |
| 17.01.2022 | Seegene's Allplex™ SARS CoV-2 FluA/FluB/RSV Assay approved under Health Canada's Interim Order | SEOUL, South Korea, Jan. 17, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostic company, announced it has received approval of its Allplex™ SARS CoV-2 FluA/FluB/RSV Assay under Health Canada's Interim ... |
| 13.01.2022 | Seegene Unveils Blueprint for the Future of Molecular Diagnostics, Including Open Development Platform at the 40th Annual J.P. Morgan Healthcare Conference | SEOUL, South Korea, Jan. 13, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics (MDx) company, today, unveiled its blueprint for the future during a presentation at the 40th annual J.P. Morgan Healthc... |
| 29.12.2021 | Seegene Airlifts 1.7 million COVID-19 Tests to Israel Battling the Omicron Variant by a charter plane | On December 29, Seegene to deliver Allplex™ SARS-CoV-2 Master Assay that can preemptively detect the Omicron variant at the primary screening stage
Earlier this month, the company has hired a private plane to deliver 2.8 million COVID-19 di... |
| 27.10.2021 | Launch of Seegene's STARlet-AIOS: All-in-One System Fulfills Critical Need for Fully Automated, High-Throughput Real-Time PCR Testing | A true walk away 'sample to answer' molecular diagnostic system designed for high throughput testing, offering a time-efficient and seamless workflow for clinical laboratories
Utilizes Seegene's patented, cutting-edge high multiplex real-ti... |
| 13.07.2021 | Seegene Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Variants Including the Delta and Delta Plus | Seegene launches new multiplex PCR test capable of screening six SARS-CoV-2 variants including the Delta and Delta Plus variants attributable for a recent surge in global COVID-19 cases.
The new CE-IVD marked variants detection kit to diffe... |
| 22.04.2021 | Seegene : to supply COVID-19 diagnostic tests worth 16 mil. GBP to Scotland, triple the sales volume seen last year | ▪Second public procurement agreement after Italy's procurement deal worth EUR 89.3 million
SEOUL, South Korea, April 21, 2021 /CNW/ -- Seegene Inc. (KQ 096530), a leading biotechnology firm said it began supplying its COVID-19 diagnostic te... |
| 12.04.2021 | Seegene begins exporting its latest COVID-19 variant tests around the world to help contain spread of pandemic
USA - English USA - English | |
| 12.04.2021 | SEEGENE, INC.
Seegene : begins exporting its latest COVID-19 variant tests around the world to help contain spread of pandemic | Seegene can produce 300,000 variant diagnostic test kits, capable of testing 30 million people every month
SEOUL, South Korea, April 12, 2021 /CNW/ -- Seegene Inc. (KQ 096530), a biotechnology company specializing in molecular diagnostics, ... |
| 03.03.2021 | Seegene : Latest COVID-19 Test Can Simultaneously Target 4 Genes of SARS-CoV-2 and Recognize Multiple Virus Variants | Seegene's new product filters COVID-19 and variants during primary PCR testing in 1 hr 55 minutes
Seegene's proprietary high multiplex technology enables detection of 10 different targets
S. Korean firm to research additional versions of va... |
| 27.03.2020 | Korea’s response to Covid-19 was widely praised. Startups had a lot to do with it | CommunityOpinionStartups
Nathan Millard · 30 Mar 2020 · 6 min readKorea’s response to Covid-19 was widely praised. Startups had a lot to do with it
South Korea is increasingly attracting attention for its use of technology to fight the spre... |